All In Biotech

Drug Trial Radar · NCT00163527

Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)

A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Chronic Asthma

Last checked: Nov 19, 2026Latest source record: Dec 2, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,054 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,054

Actual

Start

Apr 2003

Primary completion

Nov 2005

Study completion Nov 2005

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Sep 14, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma. The aim of the study is to investigate the effect of roflumilast taken orally together with low dose inhaled corticosteroids on lung function. Roflumilast will be administered at one dose level once daily together with inhaled corticosteroids at one dose level twice daily. The study duration consists of a baseline period (2 to 6 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.

Conditions

  • Asthma

Interventions

  • RoflumilastDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. change in forced expiratory volume in 1 second from baseline to final visit.

Locations

24 sites in 24 countries. Site status is shown where the registry gives one.

  • ALTANA Pharma

    Cities in Georgia, Georgia

  • ALTANA Pharma

    Cities in Austria, Austria

  • ALTANA Pharma

    Cities in Croatia, Croatia

  • ALTANA Pharma

    Cities in the Czech Repulik, Czechia

  • ALTANA Pharma

    Cities in Finland, Finland

  • ALTANA Pharma

    Cities in France, France

  • ALTANA Pharma

    Cities in Greece, Greece

  • ALTANA Pharma

    Cities in Hungary, Hungary

  • ALTANA Pharma

    Cities in India, India

  • ALTANA Pharma

    Cities in Ireland, Ireland

  • ALTANA Pharma

    Cities in Italy, Italy

  • ALTANA Pharma

    Cities in New Zealand, New Zealand

  • ALTANA Pharma

    Cities in Norway, Norway

  • ALTANA Pharma

    Cities in Pakistan, Pakistan

  • ALTANA Pharma

    Cities in the Philippines, Philippines

  • ALTANA Pharma

    Cities in Poland, Poland

  • ALTANA Pharma

    Cities in Portugal, Portugal

  • ALTANA Pharma

    Cities in the Russian Federation, Russia

  • ALTANA Pharma

    Sites in Singapore, Singapore

  • ALTANA Pharma

    Cities in South Africa, South Africa

  • ALTANA Pharma

    Cities in Spain, Spain

  • ALTANA Pharma

    Cities in Taiwan, Taiwan

  • ALTANA Pharma

    Cities in Thailand, Thailand

  • ALTANA Pharma

    Cities in the United Kindom, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.